Stock FGEN FIBROGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights FibroGen, Inc.

Equities

FGEN

US31572Q8087

Market Closed - Nasdaq
Other stock markets
 21:00:00 08/05/2024 BST 		Pre-market 12:55:20
1.13 USD -17.52% Intraday chart for FibroGen, Inc. 1.12 -0.88%
05-07 Top Premarket Gainers MT
05-06 Transcript : FibroGen, Inc., Q1 2024 Earnings Call, May 06, 2024

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Premarket Gainers
MT
Earnings Flash (FGEN) FIBROGEN Posts Q1 Revenue $55.9M, vs. Street Est of $36.4M
MT
FibroGen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting
CI
Top Midday Decliners
MT
FibroGen Says Phase 1 Study of Potential Prostate Cancer Treatment Shows Promise
MT
Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
CI
FibroGen regains rights to anemia drug from AstraZeneca
RE
FibroGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (FGEN) FIBROGEN Reports Q4 Revenue $27.1M, vs. Street Est of $38.8M
MT
FibroGen, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
FibroGen, Inc. Regains All Rights to Roxadustat from Astrazeneca in the United States and Other Astrazeneca Territories, Except China and South Korea
CI
FibroGen, Inc. Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network?s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer
CI
FibroGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Earnings Flash (FGEN) FIBROGEN Reports Q3 Revenue $40.1M, vs. Street Est of $36.8M
MT
Fibrogen, Inc. Announces Topline Results from Lelantos-2, A Phase 3 Clinical Study of Pamrevlumab in Ambulatory Muscular Dystrophy
CI
FibroGen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Earnings Flash (FGEN) FIBROGEN Posts Q2 Revenue $44.3M, vs. Street Est of $34.8M
MT
Fibrogen, Inc. Reports Topline Results from Its Phase 3 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
CI
FibroGen, Inc. Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FGEN Stock
  4. News FibroGen, Inc.
  5. Highlights